ViewRay (VRAYQ) 10-Q 12 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 01, 2019
Cover [Abstract]
Entity Registrant Name	ViewRay, Inc.
Entity Central Index Key	0001597313
Document Type	10-Q
Trading Symbol	VRAY
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		99,406,356
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-37725
Entity Tax Identification Number	42-1777485
Entity Address, Address Line One	2 Thermo Fisher Way
Entity Address, City or Town	Oakwood Village
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	44146
City Area Code	(440)
Local Phone Number	703-3210
Title of 12(b) Security	Common Stock
Entity Interactive Data Current	Yes
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 90,756	$ 167,432
Accounts receivable	33,301	36,867
Inventory	59,622	49,462
Deposits on purchased inventory	4,883	8,142
Deferred cost of revenue	3,056	9,736
Prepaid expenses and other current assets	4,672	6,045
Total current assets	196,290	277,684
Property and equipment, net	23,437	13,958
Restricted cash	1,442	1,933
Intangible assets, net	57	0
Right-of-use assets	12,254	0
Other assets	2,255	1,395
TOTAL ASSETS	235,735	294,970
Current liabilities:
Accounts payable	11,648	10,207
Accrued liabilities	18,835	9,983
Customer deposits	10,746	19,968
Operating lease liability, current	2,139	0
Deferred revenue, current	9,644	13,731
Total current liabilities	53,012	53,889
Deferred revenue, net of current portion	4,516	5,744
Long-term debt	55,489	55,364
Warrant liabilities	3,194	11,844
Operating lease liability, noncurrent	11,067	0
Other long-term liabilities	562	820
TOTAL LIABILITIES	127,840	127,661
Commitments and contingencies (Note 6)	0	0
Stockholders’ equity:
Convertible preferred stock, par value of $0.01 per share; 10,000,000 shares authorized at September 30, 2019 and December 31, 2018; no shares issued and outstanding at September 30, 2019 and December 31, 2018	0	0
Common stock, par value of $0.01 per share; 300,000,000 shares authorized at September 30, 2019 and December 31, 2018; 99,405,805 and 96,332,023 shares issued and outstanding at September 30, 2019 and December 31, 2018	984	952
Additional paid-in capital	590,878	565,334
Accumulated deficit	(483,967)	(398,977)
TOTAL STOCKHOLDERS’ EQUITY	107,895	167,309
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 235,735	$ 294,970

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Preferred stock, par value per share	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value per share	$ 0.01	$ 0.01
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	99,405,805	96,332,023
Common stock, shares outstanding	99,405,805	96,332,023

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue:
Total revenue	$ 20,862	$ 17,666	$ 71,313	$ 60,299
Cost of revenue:
Total cost of revenue	20,288	17,302	72,857	54,296
Gross margin	574	364	(1,544)	6,003
Operating expenses:
Research and development	5,641	4,347	17,135	12,506
Selling and marketing	7,297	3,384	19,845	10,024
General and administrative	19,381	16,721	49,888	37,070
Total operating expenses	32,319	24,452	86,868	59,600
Loss from operations	(31,745)	(24,088)	(88,412)	(53,597)
Interest income	484	2	1,391	6
Interest expense	(1,069)	(1,974)	(2,902)	(5,758)
Other income (expense), net	11,499	(6,792)	4,933	(307)
Loss before provision for income taxes	(20,831)	(32,852)	(84,990)	(59,656)
Provision for income taxes	0	0	0	0
Net loss and comprehensive loss	(20,831)	(32,852)	(84,990)	(59,656)
Amortization of beneficial conversion feature related to Series A convertible preferred stock	0	0	0	(2,728)
Net loss attributable to common stockholders, basic and diluted	$ (20,831)	$ (32,852)	$ (84,990)	$ (62,384)
Net loss per share, basic and diluted	$ (0.21)	$ (0.39)	$ (0.87)	$ (0.82)
Weighted-average common shares used to compute net loss per share attributable to common stockholders, basic and diluted	99,039,789	84,920,996	97,763,964	76,185,346
Product
Revenue:
Total revenue	$ 18,696	$ 16,492	$ 65,475	$ 57,237
Cost of revenue:
Total cost of revenue	18,521	15,199	63,368	49,564
Service
Revenue:
Total revenue	2,048	1,056	5,482	2,706
Cost of revenue:
Total cost of revenue	1,767	2,103	9,489	4,732
Distribution Rights
Revenue:
Total revenue	$ 118	$ 118	$ 356	$ 356

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Direct Registered Offering	At The Market Offering Program	Convertible Preferred Stock	Convertible Preferred StockDirect Registered Offering	Additional Paid-in Capital	Additional Paid-in CapitalDirect Registered Offering	Additional Paid-in CapitalAt The Market Offering Program	Additional Paid-in CapitalConvertible Preferred Stock	Additional Paid-in CapitalConvertible Preferred StockDirect Registered Offering	Common Stock	Common StockDirect Registered Offering	Common StockAt The Market Offering Program	Accumulated Deficit	Accumulated DeficitDirect Registered Offering
Balance at Dec. 31, 2017	$ 1,987					$ 321,174					$ 666			$ (319,853)
Balance, shares at Dec. 31, 2017											67,653,974
Issuance of common stock from option exercises	3,571					3,555					$ 16
Issuance of common stock from option exercises, shares											1,607,108
Stock-based compensation	10,052					10,052
Issuance of common stock from releases of restricted stock units, shares											38,856
Issuance of common stock from warrant exercises						(1)					$ 1
Issuance of common stock from warrant exercises, shares											123,607
Issuance of common stock, value		$ 30,093	$ 162,141				$ 30,052	$ 161,954				$ 41	$ 187
Issuance of common stock, share												4,090,000	18,681,746
Issuance of preferred Series A stock upon direct registered offering, value		22,207			$ 30		2,728			$ 22,177					$ (2,728)
Issuance of preferred Series A stock upon direct registered offering, share					3,000,581
Issuance of common stock warrants in connection with direct registered offering		$ 6,623					$ 6,623
Conversion of Series A preferred stock into common stock, value				$ (30)		22,177			$ (22,177)		$ 30
Conversion of Series A preferred stock into common stock, share				(3,000,581)							3,000,581
Reclassification of warrant liability to additional paid-in capital upon warrant exercises	342					342
Net loss	(59,656)													(59,656)
Balance at Sep. 30, 2018	177,360					558,656					$ 941			(382,237)
Balance, shares at Sep. 30, 2018											95,195,872
Balance at Jun. 30, 2018	37,966					386,610					$ 741			(349,385)
Balance, shares at Jun. 30, 2018											75,188,832
Issuance of common stock from option exercises	2,856					2,844					$ 12
Issuance of common stock from option exercises, shares											1,210,169
Stock-based compensation	7,179					7,179
Issuance of common stock from releases of restricted stock units, shares											26,388
Issuance of common stock from warrant exercises						(1)					$ 1
Issuance of common stock from warrant exercises, shares											121,834
Issuance of common stock, value			$ 161,869					$ 161,682					$ 187
Issuance of common stock, share													18,648,649
Reclassification of warrant liability to additional paid-in capital upon warrant exercises	342					342
Net loss	(32,852)													(32,852)
Balance at Sep. 30, 2018	177,360					558,656					$ 941			(382,237)
Balance, shares at Sep. 30, 2018											95,195,872
Balance at Dec. 31, 2018	167,309					565,334					$ 952			(398,977)
Balance, shares at Dec. 31, 2018											96,332,023
Issuance of common stock from option exercises	$ 9,641					9,618					$ 23
Issuance of common stock from option exercises, shares	2,219,251										2,219,251
Stock-based compensation	$ 14,369					14,369
Issuance of common stock from releases of restricted stock units						(4)					$ 4
Issuance of common stock from releases of restricted stock units, shares											390,332
Tax withholding paid on behalf of employees for stock-based awards	(2,410)					(2,410)
Issuance of common stock from warrant exercises						(5)					$ 5
Issuance of common stock from warrant exercises, shares											464,199
Reclassification of warrant liability to additional paid-in capital upon warrant exercises	3,976					3,976
Net loss	(84,990)													(84,990)
Balance at Sep. 30, 2019	107,895					590,878					$ 984			(483,967)
Balance, shares at Sep. 30, 2019											99,405,805
Balance at Jun. 30, 2019	122,917					585,080					$ 973			(463,136)
Balance, shares at Jun. 30, 2019											98,259,203
Issuance of common stock from option exercises	1,438					1,433					$ 5
Issuance of common stock from option exercises, shares											517,624
Stock-based compensation	4,910					4,910
Issuance of common stock from releases of restricted stock units						(3)					$ 3
Issuance of common stock from releases of restricted stock units, shares											335,863
Tax withholding paid on behalf of employees for stock-based awards	(2,410)					(2,410)
Issuance of common stock from warrant exercises						(3)					$ 3
Issuance of common stock from warrant exercises, shares											293,115
Reclassification of warrant liability to additional paid-in capital upon warrant exercises	1,871					1,871
Net loss	(20,831)													(20,831)
Balance at Sep. 30, 2019	$ 107,895					$ 590,878					$ 984			$ (483,967)
Balance, shares at Sep. 30, 2019											99,405,805

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018
At The Market Offering Program
Offering cost	$ 10,631	$ 10,637
Direct Registered Offering
Offering cost	$ 0	$ 177

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (84,990)	$ (59,656)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,156	2,561
Stock-based compensation	14,369	10,052
Accretion on asset retirement obligation	22	26
Change in fair value of warrant liabilities	(4,674)	(116)
Loss on disposal of property and equipment	0	1
Amortization of debt discount and interest accrual	472	2,703
Product upgrade reserve	4,431	0
Changes in operating assets and liabilities:
Accounts receivable	3,566	(2,351)
Inventory	(10,514)	(22,412)
Deposits on purchased inventory	3,259	1,478
Deferred cost of revenue	1,951	2,327
Prepaid expenses and other assets	852	(2,262)
Accounts payable	1,231	(4,067)
Accrued expenses and other long-term liabilities	4,774	6,732
Customer deposits and deferred revenue	(14,537)	(12,445)
Net cash used in operating activities	(76,632)	(77,429)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(7,541)	(2,814)
Purchase of intangible asset	(57)	0
Net cash used in investing activities	(7,598)	(2,814)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of debt issuance cost	(168)	0
Proceeds from the exercise of stock options	9,641	3,571
Payments for taxes related to net share settlement of equity awards	(2,410)	0
Net cash provided by financing activities	7,063	224,635
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(77,167)	144,392
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — BEGINNING OF PERIOD	169,365	58,532
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — END OF PERIOD	92,198	202,924
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	2,879	3,055
Cash paid for taxes	7	0
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Fair value of common stock warrants reclassified from liability to additional paid-in capital upon exercise	3,976	342
Right-of-use assets obtained in exchange for new operating lease liabilities	1,647	0
Transfer of property and equipment from inventory and deferred cost of revenue	4,446	1,700
Purchases of property and equipment in accounts payable and accrued liabilities	491	129
Public Offering
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from offering of common stock, gross	0	172,500
Payment of offering costs related to common stock issuance	0	(10,631)
At The Market Offering Program
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from offering of common stock, gross	0	278
Payment of offering costs related to common stock issuance	0	(6)
Direct Registered Offering
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from offering of common stock, gross	0	59,100
Payment of offering costs related to common stock issuance	$ 0	$ (177)

Background and Organization

Background and Organization	9 Months Ended
	Sep. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Background and Organization	1. Background and Organization ViewRay, Inc., or ViewRay or the Company, and its wholly-owned subsidiary ViewRay Technologies, Inc., designs, manufactures and markets MRIdian, an MR Image-Guided radiation therapy system to simultaneously image and treat cancer patients. Since inception, ViewRay Technologies, Inc. has devoted substantially all of its efforts towards research and development, initial selling and marketing activities, raising capital and the manufacturing, shipment and installation of MRIdian systems. In May 2012, ViewRay Technologies, Inc. was granted clearance from the U.S. Food and Drug Administration, or FDA, to sell MRIdian with Cobalt-60. In November 2013, ViewRay Technologies, Inc. received its first clinical acceptance of a MRIdian with Cobalt-60 at a customer site, and the first patient was treated with that system in January 2014. ViewRay Technologies, Inc. has had the right to affix the CE mark to MRIdian with Cobalt-60 in the European Economic Area since November 2014. In September 2016, the Company received the rights to affix the Conformité Européene, or CE, mark to MRIdian Linac, and in February 2017, the Company received 510(k) clearance from the FDA to market MRIdian Linac. The Company’s condensed consolidated financial statements have been prepared on the basis of the Company continuing as a going concern. The Company’s principal sources of liquidity are cash flows from public and private offerings and available borrowings under its term loan agreement, as well as cash receipts from its sales of MRIdian systems. These have historically been sufficient to meet working capital needs, capital expenditures, operating expenses, and debt service obligations. During the nine months ended September 30, 2019, the Company incurred a net loss of $85.0 million and used cash in operating activities of $76.6 million. The Company believes that its existing cash balance of $90.8 million as of September 30, 2019, together with anticipated cash proceeds from sales of MRIdian systems will be sufficient to provide liquidity to fund its operations for at least the next 12 months.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, and pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. The condensed consolidated financial statements include the accounts of ViewRay, Inc. and its wholly-owned subsidiary, ViewRay Technologies, Inc. All inter-company accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s unaudited condensed consolidated financial statements, have been included. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019 or any future period. These unaudited condensed consolidated financial statements and their notes should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018. Effective January 1, 2019, the Company adopted the Financial Accounting Standards Board, or FASB, Leases, Significant Accounting Policies The significant accounting policies used in preparation of these condensed consolidated financial statements are disclosed in the notes to consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed with the SEC on March 15, 2019, and have not changed significantly since that filing, except for the January 1, 2019 adoption of the new accounting guidance Topic 842, Leases Recent Accounting Pronouncements In August 2018, the FASB issued Accounting Standards Update, or ASU, No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement, Recently Adopted Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases Topic 842 provides several optional practical expedients in transition. The Company elected to use the package of practical expedients permitted under the transition guidance, which allows the Company not to reassess its prior conclusions about lease identification, lease classification and initial direct costs for any leases that existed prior to January 1, 2019. The Company did not elect to use the other practical expedients provided. Upon adoption, the Company recognized the right-of-use assets and operating lease liabilities totaling approximately $11.9 million and $12.6 million, respectively, to reflect the present value of remaining lease payments under existing lease arrangements with no impact to the opening balance of retained deficit as a result of adoption. The difference between the leased assets and lease liabilities represents the existing deferred rent liabilities balance, resulting from historical straight-lining of operating leases, which was effectively reclassified upon adoption to reduce the measurement of the leased assets. In determining the present value of lease payments, the Company uses the rate implicit in the lease or when such rate is not readily available, we utilize our incremental borrowing rate based on the information available at the lease commencement date. Lease expense is recognized on a straight-line basis over the expected lease term. In determining the expected lease term, the Company may include options to extend or terminate the lease when it is reasonably certain that it will exercise any such option. For more information on the impact of adoption and the disclosures required by the new standard, refer to Note 6, Commitments and Contingencies. In June 2018, the FASB issued ASU No. 2018-07, Compensation — Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting

Balance Sheet Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Balance Sheet Components	3. Balance Sheet Components Property and Equipment, Net Property and equipment consisted of the following (in thousands): September 30, 2019 December 31, 2018 Prototype $ 12,512 $ 12,425 Machinery and equipment 15,588 12,654 Leasehold improvements 5,055 4,600 Furniture and fixtures 998 636 Software 1,389 1,250 Construction in progress 8,806 148 Property and equipment, gross 44,348 31,713 Less: accumulated depreciation and amortization (20,911 ) (17,755 ) Property and equipment, net $ 23,437 $ 13,958 Depreciation and amortization expense related to property and equipment were $1.2 million and $0.9 million during the three months ended September 30, 2019 and 2018, and $3.2 million and $2.5 million during the nine months ended September 30, 2019 and 2018, respectively. Intangible Assets In September 2019, the Company entered into a licensing agreement (the “License”) with VU University Medical Center, or VUmc, whereby VUmc granted the Company a worldwide exclusive license to developed strategies for fast stereotactic MR-guided adaptive radiation therapy for $57 thousand. The License is amortized on a straight-line basis over ten years. During the three and nine months ended September 30, 2019 and 2018, there was no intangible assets amortization expense. Accrued Liabilities Accrued liabilities consisted of the following (in thousands): September 30, 2019 December 31, 2018 Accrued payroll and related benefits $ 7,094 $ 5,047 Accrued accounts payable 2,683 3,626 Payroll withholding tax, sales and other tax payable 3,378 782 Accrued legal, accounting and professional fees 375 360 Product upgrade reserve 3,794 — Other 1,511 168 Total accrued liabilities $ 18,835 $ 9,983 Deferred Revenue Deferred revenue consisted of the following (in thousands): September 30, 2019 December 31, 2018 Deferred revenue: Product $ 3,654 $ 9,623 Service 7,991 6,981 Distribution rights 2,515 2,871 Total deferred revenue 14,160 19,475 Less: current portion of deferred revenue (9,644 ) (13,731 ) Noncurrent portion of deferred revenue $ 4,516 $ 5,744 Other Long-Term Liabilities September 30, 2019 December 31, 2018 Accrued interest, noncurrent portion $ 347 $ — Deferred rent, noncurrent portion — 628 Other 215 192 Total other-long term liabilities $ 562 $ 820

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	4. Fair Value of Financial Instruments Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The assets’ or liabilities’ fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company’s financial instruments that are carried at fair value mainly consist of Level 1 assets and Level 3 liabilities. Level 1 assets include highly liquid bank deposits and money market funds, which were not material at September 30, 2019 The gains and losses from re-measurement of Level 3 financial liabilities are recorded as part of other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. During the three and nine months ended September 30, 2019, the Company recorded a gain of $13.5 million and a gain of $8.6 million, respectively, related to the change in fair value of the 2017 and 2016 Placement Warrants. During the three and nine months ended September 30, 2018, the Company recorded a loss of $6.7 million and a gain of $0.4 million, respectively, related to the change in fair value of the 2017 and 2016 Placement Warrants. There were no transfers between Level 1, Level 2 and Level 3 in any periods presented. The following table sets forth the fair value of the Company’s financial liabilities by level within the fair value hierarchy (in thousands): At September 30, 2019 Level 1 Level 2 Level 3 Total 2017 Placement Warrants Liability $ — $ — $ 2,408 $ 2,408 2016 Placement Warrants Liability — — 786 786 Total $ — $ — $ 3,194 $ 3,194 At December 31, 2018 Level 1 Level 2 Level 3 Total 2017 Placement Warrants Liability $ — $ — $ 7,115 $ 7,115 2016 Placement Warrants Liability — — 4,729 4,729 Total $ — $ — $ 11,844 $ 11,844 The following table sets forth a summary of the changes in fair value of the Company’s Level 3 financial liabilities (in thousands): Nine Months Ended September 30, 2019 2018 Fair value, beginning of period $ 11,844 $ 22,420 Change in fair value of Level 3 financial liabilities (4,674 ) (116 ) Fair value of 2016 Placement Warrants at exercise (3,458 ) (342 ) Fair value of 2017 Placement Warrants at exercise (518 ) — Fair value, end of period $ 3,194 $ 21,962

Debt

Debt	9 Months Ended
	Sep. 30, 2019
Debt Instruments [Abstract]
Debt	5. Debt SVB Term Loan In December 2018, the Company entered into a term loan agreement, or the SVB Term Loan, with Silicon Valley Bank, for a principal amount of $56.0 million. The SVB Term Loan has a maturity date of December 1, 2023 and bears interest at a rate of 6.30% per annum to be paid monthly over the term of the loan. Beginning on December 1, 2020 (or June 1, 2021, if the Company achieves a trailing twelve-month revenue of at least a specified amount and elects to apply such later date), the Company will make thirty-six equal monthly payments of principal (or thirty equal payments, if the Company so elects). In addition, upon repayment of the SVB Term Loan in full, the Company will make a final payment equal to 3.15% of the original aggregate principal amount of the SVB Term Loan. The Company used the proceeds of the SVB Term Loan and cash on hand to repay in full its outstanding obligations under its then outstanding term loan, or the CRG Term Loan, and to pay fees and expenses related thereto. The Company accounted for the termination of the CRG Term Loan as a debt extinguishment and recorded a debt extinguishment loss of $2.4 million from the difference between the net carrying amount of debt and the amount paid. The debt extinguishment loss includes $0.3 million in write-offs of unamortized debt discount and debt issuance costs associated with the CRG Term Loan. The Company received net proceeds from the SVB Term Loan of $55.4 million after related legal and consulting fees totaling $0.6 million. Such fees are accounted for as debt discount and issuance costs and presented as a direct deduction from the carrying amount of debt on the Company’s consolidated balance sheets. Debt discount, issuance costs and the final payment are amortized or accreted as interest expense over the term of the loan using the effective interest method. The SVB Term Loan is secured by substantially all assets of the Company, except that the collateral does not include any intellectual property held by the Company, provided, however, the collateral shall include all accounts and proceeds of such intellectual property. The SVB Term Loan contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, dividends and other distributions and transactions with affiliates. The SVB Term Loan also contains financial covenants that require the Company to maintain a minimum cash balance in accounts maintained at Silicon Valley Bank or one of its affiliates or else comply with a liquidity ratio and/or a minimum revenue target. The SVB Term Loan includes standard events of default, including, among other things, subject in certain cases to customary grace periods, thresholds and notice requirements, the Company’s failure to fulfill its obligations under the SVB Term Loan or the occurrence of a material adverse change in the Company's business, operations, or condition (financial or otherwise). In the event of default by the Company under the SVB Term Loan, Silicon Valley Bank would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which the Company may be required to repay all amounts then outstanding under the SVB Loan, which could harm the Company's financial condition. The Company’s scheduled future payments on the SVB Term Loan at September 30, 2019 are as follows (in thousands): Year Ended December 31, The remainder of 2019 $ — 2020 1,555 2021 18,667 2022 18,667 2023 17,111 Total future principal payments 56,000 Less: unamortized debt discount (511 ) Carrying value of long-term debt 55,489 Less: current portion — Long-term portion $ 55,489

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies Operating Leases The Company leases office space in Oakwood Village, Ohio, Mountain View, California and Denver, Colorado under noncancelable operating lease agreements. The Company leases and occupies approximately 19,800 square feet of office space in Oakwood Village, Ohio, which expires in October 2021. In June 2014, the Company entered into an office lease agreement to lease approximately 25,500 square feet of office space located in Mountain View, California, with an original expiration date of November 2019. In June 2018, the Company entered into an amendment to extend the term of the lease agreement through July 2025. In April 2018, the Company entered into a lease agreement to lease approximately 24,600 square feet of additional office space located in Mountain View, California. The lease commenced in December 2018 and will expire in December 2025. The Company has the option to extend the term of the lease for a period of up to five years. In May 2019, the Company entered into a sub-lease agreement to lease approximately 19,800 square feet of office space located in Denver, Colorado. The sub-lease commenced in June 2019 and will expire in May 2021. In recognition of the right-of-use assets and the related lease liabilities, with the exception of the Oakwood Village, Ohio lease, the options to extend the lease term have not been included as the Company is not reasonably certain that it will exercise any such option. At September 30, 2019, the weighted-average remaining lease term in years is 5.6 years and the weighted-average discount rate used is 7.7%. During the three and nine months ended September 30, 2019, the Company recognized the following lease costs arising from lease transactions: Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Operating lease cost $ 782 $ 2,085 During the nine months ended September 30, 2019, the Company recognized the following cash flow transactions arising from lease transactions: For the Nine Months Ended September 30, 2019 Cash paid for amounts included in the measurement of lease liabilities $ 1,742 Right-of-use assets obtained in exchange for new operating lease liabilities 1,647 At September 30, 2019, the future payments and interest expense for the operating leases are as follows: Year Ending December 31, Future Payments The remainder of 2019 $ 710 2020 3,148 2021 2,831 2022 2,496 2023 2,571 2024 2,604 Thereafter 1,924 Total undiscounted cash flows $ 16,284 Less: imputed interest (3,078 ) Present value of lease liabilities $ 13,206 The rent expense for operating leases for the three and nine months ended September 30, 2018 using the accounting guidance in effect at that time was $0.5 million and $0.9 million, respectively. At December 31, 2018, the future minimum payments for the operating leases were as follows (in thousands): Year Ending December 31, Future Payments 2019 $ 2,070 2020 2,353 2021 2,424 2022 2,496 2023 2,571 Thereafter 4,532 Total future minimum payments $ 16,446 Legal Proceedings In the normal course of business, the Company may become involved in legal proceedings. The Company will accrue a liability for legal proceedings when it is probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. Patent Litigation On September 10, 2019, a complaint for patent infringement was filed by Varian Medical Systems, Inc., in U.S. District Court for the Northern District of California against the Company. Captioned Varian Medical Systems, Inc., v. ViewRay, Inc., the complaint alleges that the Company infringes two related patents, U.S. Patent Nos. 8,637,841 (the “’841 Patent”) and 9,082,520 (the “’520 Patent”). The Company filed its answer on November 1, 2019. The Company believes the allegations in the complaint are without merit and intends to vigorously defend the litigation. Class Action Litigation On September 13, 2019, a class action complaint for violation of federal securities laws was filed in U.S. District Court for the Northern District of Ohio against the Company, its chief executive officer, chief science officer and former chief financial officer. Captioned Corwin v. ViewRay, Inc., et al., the complaint, purportedly brought on behalf of all purchasers of the Company’s common stock between March 15, 2019 and August 8, 2019, alleges that the Company violated federal securities laws by issuing materially false and misleading statements that failed to disclose adverse facts concerning the Company’s business, operations, and financial results. The Company believes the allegations in the complaint are without merit and intends to vigorously defend the litigation. Given the early stage of each of the litigation matters described above, at this time we are unable to reasonably estimate possible losses or form a judgment that an unfavorable outcome is either probable or remote. However, litigation is subject to inherent uncertainties, and one or more unfavorable outcomes in any claim or litigation against us could have a material adverse effect for the period in which they are resolved and on our business generally. In addition, regardless of their merits or their ultimate outcomes, lawsuits and legal proceedings are costly, divert management attention and may materially adversely affect our reputation, even if resolved in our favor. Purchase Commitments At September 30, 2019, the Company had $4.9 million in outstanding firm purchase commitments.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2019
Revenue From Contract With Customer [Abstract]
Revenue	7. Revenue The Company derives revenue primarily from the sale of MRIdian systems and related services as well as support and maintenance services on sold systems. Revenue is categorized as product revenue, service revenue and distribution rights revenue. The following table presents revenue disaggregated by type and geography (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 U.S. Product $ 6,107 $ 6,187 $ 28,394 $ 25,775 Service 1,140 566 3,094 1,464 Total U.S. revenue $ 7,247 $ 6,753 $ 31,488 $ 27,239 Outside of U.S. ("OUS") Product $ 12,589 $ 10,305 $ 37,081 $ 31,462 Service 908 490 2,388 1,242 Distribution rights 118 118 356 356 Total OUS revenue $ 13,615 $ 10,913 $ 39,825 $ 33,060 Total Product $ 18,696 $ 16,492 $ 65,475 $ 57,237 Service 2,048 1,056 5,482 2,706 Distribution rights 118 118 356 356 Total revenue $ 20,862 $ 17,666 $ 71,313 $ 60,299 Product Revenue Beginning in the second quarter of 2019, the Company determined that the MRIdian system and installation of the MRIdian system, which had previously been one performance obligation, are now two performance obligations as they are capable of being distinct and are distinct within the context of the system contracts. This change occurred due primarily to changes in facts and circumstances, whereby there are now readily available resources outside the Company that can perform the system installations. Additionally, certain revenue contracts have terms that result in the control of the system transferring to the customer upon delivery and inspection, as opposed to historically upon customer acceptance. For contracts in which control of the system transfers upon delivery and inspection, the Company recognizes revenue for the systems at the point in time when delivery and inspection by the customer has occurred. For these same contracts, the Company recognizes installation revenue over the period of installation as the installation services are performed and control is transferred to the customer. For all contracts in which control continues to transfer upon post-implementation customer acceptance, revenue for the system and installation will continue to be recognized upon customer acceptance. Certain customer contracts with distributors do not require ViewRay installation at the ultimate user site, and the distributors may either perform the installation themselves or hire another party to perform the installation. For sales of MRIdian systems for which the Company is not responsible for installation, revenue recognition occurs when the entire system is delivered and inspected, which is when the control of the system is transferred to the customer. Distribution agreement In connection with the distribution agreement entered into in December 2014, between the Company and Itochu Corporation, or Itochu, the Company received a distribution fee of $4.0 million in three installments from Itochu for serving as the Company’s exclusive distributor for the sale and delivery of its MRIdian systems within Japan. In August 2016, the Company started recognizing distribution rights revenue ratably over the remaining term of the exclusive distribution agreement of approximately 8.5 years. A time-elapsed method is used to measure progress because control is transferred evenly over the remaining contractual period. Contract Balances The timing of revenue recognition, billings and cash collections results in short-term and long-term trade receivables, customer deposits, deferred revenues and deferred cost of revenue on the condensed consolidated balance sheets. Trade receivables are recorded at the original invoiced amount, net of an estimated allowance for doubtful accounts. Trade credit is generally extended on a short-term basis. The Company occasionally provides for long-term trade credit for its maintenance services so that the period between when the services are rendered to its customers and when the customers pay for that service is within one year. Thus, the Company’s trade receivables do not bear interest or contain a significant financing component. Long-term trade receivables of $0.2 million and $0.4 million were reported within other assets in the condensed consolidated balance sheets at September 30, 2019 and at December 31, 2018, respectively. These amounts are billed in accordance with the terms of the customer contracts to which they relate and are expected to be collected three to four years from the date of invoice as the underlying maintenance services are rendered. At times, billing occurs subsequent to revenue recognition, resulting in an unbilled receivable which represents a contract asset. This contract asset is recorded as an unbilled receivable and reported as part of accounts receivable on the condensed consolidated balance sheets. Trade receivables are periodically evaluated for collectability based on past credit history of the respective customers and their current financial condition. Changes in the estimated collectability of trade receivables are included in the results of operations for the period in which the estimate is revised. Trade receivables that are deemed uncollectible are offset against the allowance for doubtful accounts. The Company generally does not require collateral for trade receivables. There were no allowances for doubtful accounts recorded at September 30, 2019 or December 31, 2018. Customer deposits represent payments received in advance of system installation. For domestic and international sales, advance payments received prior to inventory shipments are recorded as customer deposits. Advance payments are subsequently reclassified to deferred revenue upon inventory shipment. All customer deposits, including those that are expected to be a deposit for more than one year, are classified as current liabilities based on consideration of the Company’s normal operating cycle (the time between acquisition of the inventory components and the final cash collection from customers on these inventory components) which is in excess of one year. Deferred revenue consists of deferred product revenue and deferred service revenue. Deferred product revenue arises from timing differences between the fulfillment of contract obligations and satisfaction of all revenue recognition criteria consistent with the Company’s revenue recognition policy. Deferred service revenue results from the advance billing for services to be delivered over a period of time. Deferred revenues expected to be realized within one year or normal operating cycle are classified as current liabilities. Deferred cost of revenue consists of cost for inventory items that have been shipped, but revenue recognition has not yet occurred. Deferred cost of revenue is included as part of current assets as the corresponding deferred product revenue is expected to be realized within one year or the Company’s normal operating cycle. During the three and nine months ended September 30, 2019, the Company recognized $2.4 million and $11.9 million, respectively, of revenues that were included in the deferred revenue balance at the beginning of each reporting period. During the three and nine months ended September 30, 2018, the Company recognized $12.2 million and $18.3 million, respectively, of revenues that were included in the deferred revenue balance at the beginning of each reporting period. Variable Consideration The Company records revenue from customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company estimates the transaction price at contract inception, including any variable consideration, and updates the estimate each reporting period for any changes. For the three and nine months ended September 30, 2019 the Company recognized $0.0 million and $0.9 million, respectively, in revenue from performance obligations satisfied in a prior period. The cumulative catch-up adjustment resulted from a change in transaction price related to variable consideration that was constrained in prior periods.

Equity Financing

Equity Financing	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Equity Financing	8. Equity Financing Public Offering of Common Stock On August 14, 2018, the Company entered into an underwriting agreement with Morgan Stanley & Co. LLC and Jefferies LLC, as representatives of several underwriters, or the “Underwriters”, in connection with the issuance and sale of 16,216,217 shares of the Company’s common stock at a public offering price of $9.25 per share. In addition, the Company granted the Underwriters a 30-day option to purchase up to 2,432,432 additional shares of common stock on the same terms, which the Underwriters exercised in full. The Company completed the offering on August 17, 2018 under which it received aggregate net proceeds of approximately $161.9 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company. Direct Registered Offerings In February 2018, the Company entered into a securities purchase agreement pursuant to which it sold (i) 4,090,000 shares of its common stock; (ii) 3,000,581 shares of its Series A convertible preferred stock and (iii) warrants to purchase 1,418,116 shares of its common stock, or the 2018 Offering Warrants, for total gross proceeds of $59.1 million, or the March 2018 Direct Registered Offering. The March 2018 Direct Registered Offering was closed on March 5, 2018. The 2018 Offering Warrants have an exercise price of $8.31 per share, became exercisable upon issuance and expire in March 2025. Private Placements In September 2016, the Company completed the final closing of a private placement offering, or the 2016 Private Placement, through which it sold (i) 4,602,506 shares of its common stock and (ii) warrants that provide the warrant holders the right to purchase 1,380,745 shares of common stock, or the 2016 Placement Warrants, and raised total gross proceeds of $13.8 million. The 2016 Placement Warrants have an exercise price of $2.95 per share, are exercisable at any time at the option of the holder and expire seven years from the date of issuance. In January 2017, the Company completed the final closing of a private placement offering, or the 2017 Private Placement, through which it sold (i) 8,602,589 shares of its common stock and (ii) warrants that provide the warrant holders the right to purchase 1,720,512 shares of its common stock, or the 2017 Placement Warrants, and raised total gross proceeds of $26.1 million. The 2017 Placement Warrants have an exercise price of $3.17 per share, became exercisable in July 2017 and expire in January 2024. At-The-Market Offering of Common Stock In January 2017, the Company filed a shelf registration statement on Form S-3 with the SEC, which included a base prospectus covering the offering, issuance and sale of up to a maximum aggregate offering of $75.0 million of the Company’s common stock, preferred stock, debt securities, warrants, purchase contracts and/or units. In January and April 2017, the Company agreed to sell up to a cumulative $50.0 million of its common stock in accordance with the terms of a sales agreement with , pursuant to an at-the-market offering program in accordance with Rule 415(a)(4) under the Securities Act. In January 2019, the Company filed a registration statement with the SEC which covers the offering, issuance and sale of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants, purchase contracts and/or units, including up to $100.0 million of the Company’s common shares pursuant to the Company’s at-the-market offering program with FBR. As of September 30, 2019, the Company has sold approximately $40.4 million under this at-the-market offering program. During the nine months ended September 30, 2018, the Company sold approximately $0.3 million under this at-the-market offering program.

Warrants

Warrants	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Warrants	9 . Warrants Equity Classified Common Stock Warrants In connection with a debt financing in December 2013, the Company issued warrants to purchase 128,231 shares of its common stock with an exercise price of $5.84 per share. These warrants were exercised during the three months ended September 30, 2019 and the Company issued 36,457 shares of its common stock upon the net exercise of the 128,231 warrants. None of these warrants remained outstanding at September 30, 2019. In connection with the merger of the Company and ViewRay Technologies, Inc. in July 2015, or the Merger, in July and August 2015, the Company conducted a private placement offering during which the Company the five-year anniversary of its date of issuance In connection with the March 2018 Direct Registered Offering, the Company issued warrants to purchase 1,418,116 shares of common stock at an exercise price of $8.31 per share, or the 2018 Offering Warrants. The 2018 Offering Warrants became exercisable upon issuance and expire in March 2025. None of the 2018 Offering Warrants have been exercised to date and they all remained outstanding at September 30, 2019. As separate classes of securities were issued in a bundled transaction, the gross proceeds from the March 2018 Direct Registered Offering of $59.1 million was allocated to common stock, Series A convertible preferred stock and the 2018 Offering Warrants based on their respective relative fair value upon issuance. The aggregate fair value of the 2018 Offering Warrants of $7.4 million was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected term of seven years, expected volatility of 62.5%, risk-free interest rate of 2.8% and expected dividend yield of 0%. The allocated proceeds from the 2018 Offering Warrants of $6.6 million was recorded in additional paid-in-capital. Liability Classified Common Stock Warrants In connection with private placement offerings in 2017 and 2016, the Company issued common stock warrants, or the 2017 and 2016 Placement Warrants, which contain protection whereby the warrant holders will have the right to receive cash in the amount equal to the Black-Scholes value of the warrants upon the occurrence of a Change of Control, as defined in the 2017 and 2016 Placement Warrants. The 2017 and 2016 Placement Warrants were accounted for as a liability at the date of issuance and are adjusted to fair value at each balance sheet date, with the change in fair value recorded as a component of other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. The key terms of the 2017 and 2016 Placement Warrants are as follows: Issuance Date Term Exercise Price Per Share Warrants Exercised during the Nine Months Ended September 30, 2019 Warrants Outstanding at September 30, 2019 2017 Placement Warrants January 2017 7 years $ 3.17 90,642 1,618,890 2016 Placement Warrants August and September 2016 7 years $ 2.95 593,352 537,263 Total 683,994 2,156,153 During the three and nine months ended September 30, 2019, the Company recorded a gain of $13.5 million and a gain of $8.6 million, respectively, related to the change in fair value of the 2016 and 2017 Placement Warrants. During the three and nine months ended September 30, 2018, the Company recorded a loss of $6.7 million and a gain of $0.4 million, respectively, related to the change in fair value of the 2016 and 2017 Placement Warrants. The fair value of the 2016 and 2017 Placement Warrants at September 30, 2019 and December 31, 2018, respectively, was estimated using the Black-Scholes option-pricing model and the following weighted-average assumptions: 2017 Placement Warrants 2016 Placement Warrants September 30, 2019 December 31, 2018 September 30, 2019 December 31, 2018 Expected term (in years) 4.3 5.1 3.9 4.7 Expected volatility 67.9% 60.8% 67.3% 60.9% Risk-free interest rate 1.6% 2.5% 1.6% 2.5% Expected dividend yield 0% 0% 0 0%

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	1 0 . Stock-Based Compensation A summary of the Company’s stock option activity and related information is as follows: Options Outstanding Shares Available for Grant Number of Stock Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (In thousands) Balance at December 31, 2018 1,908,626 11,603,708 $ 6.64 7.6 $ 10,151 Additional options authorized 3,853,280 Options granted (2,624,505 ) 2,624,505 8.19 Options exercised — (2,219,251 ) 4.34 Options canceled 553,585 (553,585 ) 6.73 Withheld shares to pay for taxes on RSU released shares 253,986 RSUs granted (708,144 ) RSUs canceled 70,732 Balance at September 30, 2019 3,307,560 11,455,377 $ 7.58 7.9 $ 1,011 Vested and exercisable at September 30, 2019 4,575,393 $ 6.25 6.2 $ 1,010 Vested and expected to vest at September 30, 2019 10,793,250 $ 7.38 7.7 $ 1,010 The weighted-average grant date fair value of options granted to employees were $4.71 and $5.02 per share during the nine months ended September 30, 2019 and 2018, respectively. The grant date fair values of options vested were $11.4 million and $4.3 million during the nine months ended September 30, 2019 and 2018, respectively. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The aggregate intrinsic values of options exercised were $7.8 million and $11.6 million during the nine months ended September 30, 2019 and 2018, respectively. At September 30, 2019, total unrecognized compensation cost related to stock options granted to employees, net of estimated forfeitures, was $29.0 million which is expected to be recognized over a weighted-average period of 2.9 years. Determination of Fair Value The determination of the fair value of stock options on the date of grant using an option-pricing model is affected by the estimated fair value of the Company’s common stock, as well as assumptions regarding a number of complex and subjective variables. The variables used to calculate the fair value of stock options using the Black-Scholes option-pricing model include actual and projected employee stock option exercise behaviors, expected price volatility of the Company’s common stock, the risk-free interest rate and expected dividends. Each of these inputs is subjective and generally requires significant judgment to determine. The fair value of employee stock options is estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumptions: Nine Months Ended September 30, 2019 2018 Expected term (in years) 6.0 6.0 Expected volatility% 60.7% 60.4% Risk-free interest rate% 2.4% 2.8% Expected dividend yield% 0.0% 0.0% Restricted Stock Units From time to time, the Company grants Restricted Stock Units, or RSUs, to its Board of Directors and certain employees for their services. The RSUs granted to board members are either fully vested upon issuance or vest over a period of time from the grant date and will be released and settled upon termination of the board member’s services or the occurrence of a change in control event. In January 2019, the Company granted RSUs to its Board of Directors as part of the director compensation program. In March 2019, the Company began granting RSUs to certain employees. These RSUs vest in equal annual installments over either two or three years from the grant date and are subject to the participants continuing service to the Company over that period. The fair value of RSUs is based on the closing market price of the Company’s common stock on the grant date. RSUs Number of Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2018 1,736,234 $ 9.65 RSUs granted 708,144 7.79 RSUs vested (631,252 ) 9.40 Unvested at September 30, 2019 1,813,126 $ 9.13 Vested and unreleased 104,173 Outstanding at September 30, 2019 1,917,299 The total grant date fair value of RSUs awarded was $5.5 million for the nine months ended September 30, 2019. The total fair value of RSUs vested was $5.9 million for the nine months ended September 30, 2019. During the nine months ended September 30, 2019, the RSUs that vested were net share settled such that the Company withheld shares with value equivalent to the employees’ obligation for the applicable income and other employment taxes and remitted the cash to the appropriate taxing authorities. The total shares withheld were approximately million and were based on the value of the RSUs on their respective vesting dates as determined by the Company’s closing stock price. Total payments for the employees’ tax obligations to taxing authorities were $2.4 million for the nine months ended September 30, 2019 and are reflected as a financing activity within the Condensed Consolidated Statement of Cash Flows. These net share settlements reduced the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company. For the nine months ended September 30, 2018, the Company granted 1.8 million shares of RSUs and recorded $1.2 million in stock-based compensation expense related to the issuance of RSUs. As of September 30, 2019, total unrecognized stock-based compensation cost related to RSUs was $12.7 million, which is expected to be recognized over a weighted-average period of 1.9 years. As of September 30, 2019, 1,617,702 RSUs are expected to vest. Stock-Based Compensation Expense Total stock-based compensation expense recognized in the Company’s condensed consolidated statements of operations and comprehensive loss is classified as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Research and development $ 377 $ 511 $ 1,221 $ 1,061 Selling and marketing 368 234 980 555 General and administrative 4,165 6,434 12,168 8,436 Total stock-based compensation expense $ 4,910 $ 7,179 $ 14,369 $ 10,052 During the three and nine months ended September 30, 2019 and 2018, there was no stock-based compensation expense capitalized as a component of inventory or recognized in cost of revenue. Stock-based compensation relating to stock-based awards granted to consultants was insignificant during the three and nine months ended September 30, 2019 and 2018.

Income Tax

Income Tax	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Tax	1 1 . Income Tax Due to the current operating losses, the Company recorded zero income tax expense during the nine months ended September 30, 2019 and 2018, respectively. During these periods, the Company’s activities were limited to U.S. federal and state tax jurisdictions, as it does not have any significant foreign operations. The federal and state effective tax rate before valuation allowance is approximately 24% for the nine months ended September 30, 2019. Due to the Company’s history of cumulative losses and after considering all the available objective evidence, management concluded that it is not more likely than not that all of the Company’s net deferred tax assets will be realized. Accordingly, the Company’s deferred tax assets, which include net operating loss, or NOL, carryforwards and tax credits related primarily to research and development, continue to be subject to a valuation allowance as of September 30, 2019. The Company expects to continue to maintain a full valuation allowance until there is sufficient evidence to support recoverability of its deferred tax assets. The Company had unrecognized tax benefits of $2.1 million and $1.6 million at September 30, 2019 and December 31, 2018, respectively. The reversal of the uncertain tax benefits would not affect the effective tax rate to the extent that the Company continues to maintain a full valuation allowance against its deferred tax assets. Unrecognized tax benefits may change during the next 12 months for items that arise in the ordinary course of business. Interest and/or penalties related to income tax matters are recognized as a component of income tax expense. At September 30, 2019 and December 31, 2018, there were no accrued interest and penalties related to uncertain tax positions.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Net Loss per Share	1 2 . Net Loss per Share Since the Company was in a loss position for all periods presented, diluted net loss per common share is the same as basic net loss per common share for all periods presented, because the inclusion of all potential common shares outstanding would have an anti-dilutive effect. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented, because including them would have an anti-dilutive effect: Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Series A convertible preferred stock (if converted) — — — 494,601 Options to purchase common stock 11,350,034 11,769,686 10,613,157 10,028,174 Common stock warrants 3,866,555 4,694,837 4,200,541 4,441,885 Restricted stock units 437,933 1,457,638 1,206,267 576,464 Total 15,654,522 17,922,161 16,019,965 15,541,124

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	1 3 . Related Party Transactions In December 2004, the Company entered into a licensing agreement with the University of Florida Research Foundation, or UFRF, whereby UFRF granted the Company a worldwide exclusive license to certain of UFRF’s patents in exchange for 33,652 shares of common stock and a 1% royalty, with a minimum $0.1 million royalty payment per quarter, from sales of products developed and sold by the Company utilizing the licensed patents. Minimum royalty payments in any calendar year are credited against earned royalties for such calendar year. Royalty expenses based on 1% of net sales were $0.6 million and $0.5 million during the nine months ended September 30, 2019 and 2018, respectively, and were recorded as product cost of revenue.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, and pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. The condensed consolidated financial statements include the accounts of ViewRay, Inc. and its wholly-owned subsidiary, ViewRay Technologies, Inc. All inter-company accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s unaudited condensed consolidated financial statements, have been included. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019 or any future period. These unaudited condensed consolidated financial statements and their notes should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018. Effective January 1, 2019, the Company adopted the Financial Accounting Standards Board, or FASB, Leases,
Significant Accounting Policies	Significant Accounting Policies The significant accounting policies used in preparation of these condensed consolidated financial statements are disclosed in the notes to consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed with the SEC on March 15, 2019, and have not changed significantly since that filing, except for the January 1, 2019 adoption of the new accounting guidance Topic 842, Leases
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2018, the FASB issued Accounting Standards Update, or ASU, No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement,
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases Topic 842 provides several optional practical expedients in transition. The Company elected to use the package of practical expedients permitted under the transition guidance, which allows the Company not to reassess its prior conclusions about lease identification, lease classification and initial direct costs for any leases that existed prior to January 1, 2019. The Company did not elect to use the other practical expedients provided. Upon adoption, the Company recognized the right-of-use assets and operating lease liabilities totaling approximately $11.9 million and $12.6 million, respectively, to reflect the present value of remaining lease payments under existing lease arrangements with no impact to the opening balance of retained deficit as a result of adoption. The difference between the leased assets and lease liabilities represents the existing deferred rent liabilities balance, resulting from historical straight-lining of operating leases, which was effectively reclassified upon adoption to reduce the measurement of the leased assets. In determining the present value of lease payments, the Company uses the rate implicit in the lease or when such rate is not readily available, we utilize our incremental borrowing rate based on the information available at the lease commencement date. Lease expense is recognized on a straight-line basis over the expected lease term. In determining the expected lease term, the Company may include options to extend or terminate the lease when it is reasonably certain that it will exercise any such option. For more information on the impact of adoption and the disclosures required by the new standard, refer to Note 6, Commitments and Contingencies. In June 2018, the FASB issued ASU No. 2018-07, Compensation — Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2019
Balance Sheet Related Disclosures [Abstract]
Schedule of Property and Equipment, Net	Property and equipment consisted of the following (in thousands): September 30, 2019 December 31, 2018 Prototype $ 12,512 $ 12,425 Machinery and equipment 15,588 12,654 Leasehold improvements 5,055 4,600 Furniture and fixtures 998 636 Software 1,389 1,250 Construction in progress 8,806 148 Property and equipment, gross 44,348 31,713 Less: accumulated depreciation and amortization (20,911 ) (17,755 ) Property and equipment, net $ 23,437 $ 13,958
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following (in thousands): September 30, 2019 December 31, 2018 Accrued payroll and related benefits $ 7,094 $ 5,047 Accrued accounts payable 2,683 3,626 Payroll withholding tax, sales and other tax payable 3,378 782 Accrued legal, accounting and professional fees 375 360 Product upgrade reserve 3,794 — Other 1,511 168 Total accrued liabilities $ 18,835 $ 9,983
Schedule of Deferred Revenue	Deferred revenue consisted of the following (in thousands): September 30, 2019 December 31, 2018 Deferred revenue: Product $ 3,654 $ 9,623 Service 7,991 6,981 Distribution rights 2,515 2,871 Total deferred revenue 14,160 19,475 Less: current portion of deferred revenue (9,644 ) (13,731 ) Noncurrent portion of deferred revenue $ 4,516 $ 5,744
Schedule of Other Long Term Liabilities	Other Long-Term Liabilities September 30, 2019 December 31, 2018 Accrued interest, noncurrent portion $ 347 $ — Deferred rent, noncurrent portion — 628 Other 215 192 Total other-long term liabilities $ 562 $ 820

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Liabilities	The following table sets forth the fair value of the Company’s financial liabilities by level within the fair value hierarchy (in thousands): At September 30, 2019 Level 1 Level 2 Level 3 Total 2017 Placement Warrants Liability $ — $ — $ 2,408 $ 2,408 2016 Placement Warrants Liability — — 786 786 Total $ — $ — $ 3,194 $ 3,194 At December 31, 2018 Level 1 Level 2 Level 3 Total 2017 Placement Warrants Liability $ — $ — $ 7,115 $ 7,115 2016 Placement Warrants Liability — — 4,729 4,729 Total $ — $ — $ 11,844 $ 11,844
Summary of Changes in Fair Value of Level 3 Financial Liabilities	The following table sets forth a summary of the changes in fair value of the Company’s Level 3 financial liabilities (in thousands): Nine Months Ended September 30, 2019 2018 Fair value, beginning of period $ 11,844 $ 22,420 Change in fair value of Level 3 financial liabilities (4,674 ) (116 ) Fair value of 2016 Placement Warrants at exercise (3,458 ) (342 ) Fair value of 2017 Placement Warrants at exercise (518 ) — Fair value, end of period $ 3,194 $ 21,962

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Scheduled Future Payments on Term Loan	The Company’s scheduled future payments on the SVB Term Loan at September 30, 2019 are as follows (in thousands): Year Ended December 31, The remainder of 2019 $ — 2020 1,555 2021 18,667 2022 18,667 2023 17,111 Total future principal payments 56,000 Less: unamortized debt discount (511 ) Carrying value of long-term debt 55,489 Less: current portion — Long-term portion $ 55,489

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
Schedule of Lease Costs and Cash Flow Transactions Arising From Lease Transactions	During the three and nine months ended September 30, 2019, the Company recognized the following lease costs arising from lease transactions: Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Operating lease cost $ 782 $ 2,085 During the nine months ended September 30, 2019, the Company recognized the following cash flow transactions arising from lease transactions: For the Nine Months Ended September 30, 2019 Cash paid for amounts included in the measurement of lease liabilities $ 1,742 Right-of-use assets obtained in exchange for new operating lease liabilities 1,647
Schedule of Future Minimum Payments and Interest Expense for Operating Leases	At September 30, 2019, the future payments and interest expense for the operating leases are as follows: Year Ending December 31, Future Payments The remainder of 2019 $ 710 2020 3,148 2021 2,831 2022 2,496 2023 2,571 2024 2,604 Thereafter 1,924 Total undiscounted cash flows $ 16,284 Less: imputed interest (3,078 ) Present value of lease liabilities $ 13,206
Schedule of Future Minimum Payments for Operating Leases	At December 31, 2018, the future minimum payments for the operating leases were as follows (in thousands): Year Ending December 31, Future Payments 2019 $ 2,070 2020 2,353 2021 2,424 2022 2,496 2023 2,571 Thereafter 4,532 Total future minimum payments $ 16,446

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2019
Revenue From Contract With Customer [Abstract]
Schedule of Revenue Disaggregated by Types and Geography	The following table presents revenue disaggregated by type and geography (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 U.S. Product $ 6,107 $ 6,187 $ 28,394 $ 25,775 Service 1,140 566 3,094 1,464 Total U.S. revenue $ 7,247 $ 6,753 $ 31,488 $ 27,239 Outside of U.S. ("OUS") Product $ 12,589 $ 10,305 $ 37,081 $ 31,462 Service 908 490 2,388 1,242 Distribution rights 118 118 356 356 Total OUS revenue $ 13,615 $ 10,913 $ 39,825 $ 33,060 Total Product $ 18,696 $ 16,492 $ 65,475 $ 57,237 Service 2,048 1,056 5,482 2,706 Distribution rights 118 118 356 356 Total revenue $ 20,862 $ 17,666 $ 71,313 $ 60,299

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Schedule of Key Terms of Placement Warrants	The key terms of the 2017 and 2016 Placement Warrants are as follows: Issuance Date Term Exercise Price Per Share Warrants Exercised during the Nine Months Ended September 30, 2019 Warrants Outstanding at September 30, 2019 2017 Placement Warrants January 2017 7 years $ 3.17 90,642 1,618,890 2016 Placement Warrants August and September 2016 7 years $ 2.95 593,352 537,263 Total 683,994 2,156,153
Summary of Assumptions using Black- Scholes Option Pricing Model to estimate fair value	The fair value of the 2016 and 2017 Placement Warrants at September 30, 2019 and December 31, 2018, respectively, was estimated using the Black-Scholes option-pricing model and the following weighted-average assumptions: 2017 Placement Warrants 2016 Placement Warrants September 30, 2019 December 31, 2018 September 30, 2019 December 31, 2018 Expected term (in years) 4.3 5.1 3.9 4.7 Expected volatility 67.9% 60.8% 67.3% 60.9% Risk-free interest rate 1.6% 2.5% 1.6% 2.5% Expected dividend yield 0% 0% 0 0%

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Company's Stock Option Activity and Related Information	A summary of the Company’s stock option activity and related information is as follows: Options Outstanding Shares Available for Grant Number of Stock Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (In thousands) Balance at December 31, 2018 1,908,626 11,603,708 $ 6.64 7.6 $ 10,151 Additional options authorized 3,853,280 Options granted (2,624,505 ) 2,624,505 8.19 Options exercised — (2,219,251 ) 4.34 Options canceled 553,585 (553,585 ) 6.73 Withheld shares to pay for taxes on RSU released shares 253,986 RSUs granted (708,144 ) RSUs canceled 70,732 Balance at September 30, 2019 3,307,560 11,455,377 $ 7.58 7.9 $ 1,011 Vested and exercisable at September 30, 2019 4,575,393 $ 6.25 6.2 $ 1,010 Vested and expected to vest at September 30, 2019 10,793,250 $ 7.38 7.7 $ 1,010
Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date	The fair value of employee stock options is estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumptions: Nine Months Ended September 30, 2019 2018 Expected term (in years) 6.0 6.0 Expected volatility% 60.7% 60.4% Risk-free interest rate% 2.4% 2.8% Expected dividend yield% 0.0% 0.0%
Summary of RSU Activity (Detail)	RSUs Number of Shares Weighted Average Grant Date Fair Value Unvested at December 31, 2018 1,736,234 $ 9.65 RSUs granted 708,144 7.79 RSUs vested (631,252 ) 9.40 Unvested at September 30, 2019 1,813,126 $ 9.13 Vested and unreleased 104,173 Outstanding at September 30, 2019 1,917,299
Summary of Stock-Based Compensation Expense	Total stock-based compensation expense recognized in the Company’s condensed consolidated statements of operations and comprehensive loss is classified as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Research and development $ 377 $ 511 $ 1,221 $ 1,061 Selling and marketing 368 234 980 555 General and administrative 4,165 6,434 12,168 8,436 Total stock-based compensation expense $ 4,910 $ 7,179 $ 14,369 $ 10,052

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	Since the Company was in a loss position for all periods presented, diluted net loss per common share is the same as basic net loss per common share for all periods presented, because the inclusion of all potential common shares outstanding would have an anti-dilutive effect. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented, because including them would have an anti-dilutive effect: Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Series A convertible preferred stock (if converted) — — — 494,601 Options to purchase common stock 11,350,034 11,769,686 10,613,157 10,028,174 Common stock warrants 3,866,555 4,694,837 4,200,541 4,441,885 Restricted stock units 437,933 1,457,638 1,206,267 576,464 Total 15,654,522 17,922,161 16,019,965 15,541,124

Background and Organization - A

Background and Organization - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Net loss	$ (20,831)	$ (32,852)	$ (84,990)	$ (59,656)
Net cash used from operating activities			(76,632)	$ (77,429)
Cash and cash equivalents	$ 90,756		$ 90,756		$ 167,432

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Significant Accounting Policies [Line Items]
Operating lease, right-of-use assets	$ 12,254,000		$ 0
Operating lease, liabilities	$ 13,206,000
ASU 2016-02
Significant Accounting Policies [Line Items]
Cumulative-effect adjustment recorded to retained deficit upon adoption		$ 0
Operating lease, right-of-use assets		11,900,000
Operating lease, liabilities		$ 12,600,000

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 44,348	$ 31,713
Less: accumulated depreciation and amortization	(20,911)	(17,755)
Property and equipment, net	23,437	13,958
Prototype
Property Plant And Equipment [Line Items]
Property and equipment, gross	12,512	12,425
Machinery and Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	15,588	12,654
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	5,055	4,600
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	998	636
Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,389	1,250
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 8,806	$ 148

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Balance Sheet Components [Line Items]
Depreciation and amortization	$ 1,200,000	$ 900,000	$ 3,200,000	$ 2,500,000
Intangible assets, net	57,000		57,000		$ 0
Intangible assets amortization expense	0	$ 0	0	$ 0
License Cost
Balance Sheet Components [Line Items]
Intangible assets, net	$ 57,000		$ 57,000
Intangible assets amortizable period			10 years
Intangible assets, amortization method			straight-line basis

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Payables And Accruals [Abstract]
Accrued payroll and related benefits	$ 7,094	$ 5,047
Accrued accounts payable	2,683	3,626
Payroll withholding tax, sales and other tax payable	3,378	782
Accrued legal, accounting and professional fees	375	360
Product upgrade reserve	3,794	0
Other	1,511	168
Total accrued liabilities	$ 18,835	$ 9,983

Balance Sheet Components - Sc_3

Balance Sheet Components - Schedule of Deferred Revenue (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Deferred Revenue [Line Items]
Total deferred revenue	$ 14,160	$ 19,475
Less: current portion of deferred revenue	(9,644)	(13,731)
Noncurrent portion of deferred revenue	4,516	5,744
Product
Deferred Revenue [Line Items]
Total deferred revenue	3,654	9,623
Service
Deferred Revenue [Line Items]
Total deferred revenue	7,991	6,981
Distribution Rights
Deferred Revenue [Line Items]
Total deferred revenue	$ 2,515	$ 2,871

Balance Sheet Components - Sc_4

Balance Sheet Components - Schedule of Other Long Term Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Payables And Accruals [Abstract]
Accrued interest, noncurrent portion	$ 347	$ 0
Deferred rent, noncurrent portion	0	628
Other	215	192
Total other-long term liabilities	$ 562	$ 820

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Change in fair value of Level 3 financial liabilities			$ 4,674,000	$ 116,000
Two Thousand Sixteen And Two Thousand Seventeen Private Placement Warrants
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Change in fair value of Level 3 financial liabilities	$ 13,500,000	$ (6,700,000)	8,600,000	400,000
Transfers between Level 1 to Level 2	0	0	0	0
Transfers between Level 2 to Level 1	0	0	0	0
Transfers into or out of Level 3	$ 0	$ 0	$ 0	$ 0

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Schedule of Fair Value of Financial Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	$ 3,194	$ 11,844
Fair Value Measurement on Recurring Basis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	3,194	11,844
Fair Value Measurement on Recurring Basis | 2017 Placement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	2,408	7,115
Fair Value Measurement on Recurring Basis | 2016 Placement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	786	4,729
Level 1 | Fair Value Measurement on Recurring Basis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	0	0
Level 1 | Fair Value Measurement on Recurring Basis | 2017 Placement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	0	0
Level 1 | Fair Value Measurement on Recurring Basis | 2016 Placement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	0	0
Level 2 | Fair Value Measurement on Recurring Basis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	0	0
Level 2 | Fair Value Measurement on Recurring Basis | 2017 Placement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	0	0
Level 2 | Fair Value Measurement on Recurring Basis | 2016 Placement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	0	0
Level 3 | Fair Value Measurement on Recurring Basis
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	3,194	11,844
Level 3 | Fair Value Measurement on Recurring Basis | 2017 Placement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	2,408	7,115
Level 3 | Fair Value Measurement on Recurring Basis | 2016 Placement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total Warrant Liability	$ 786	$ 4,729

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level 3 Financial Liabilities (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Fair value, beginning of period	$ 11,844	$ 22,420
Change in fair value of Level 3 financial liabilities	(4,674)	(116)
Fair value, end of period	3,194	21,962
2016 Placement Warrants
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Fair value of Placement Warrants at exercise	(3,458)	(342)
2017 Placement Warrants
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Fair value of Placement Warrants at exercise	$ (518)	$ 0

Debt - Additional Information (

Debt - Additional Information (Detail) $ in Millions	1 Months Ended	9 Months Ended
	Dec. 31, 2018USD ($)Installment	Sep. 30, 2019USD ($)
SVB Term Loan
Debt Instrument [Line Items]
Total principal amount	$ 56
Debt maturity date	Dec. 1, 2023
Debt instrument interest rate percentage	6.30%
Frequency of periodic payment		monthly
Number of installments | Installment	36
Number of installments if achieving trailing revenue target and company so elects | Installment	30
Debt instrument description		Beginning on December 1, 2020 (or June 1, 2021, if the Company achieves a trailing twelve-month revenue of at least a specified amount and elects to apply such later date), the Company will make thirty-six equal monthly payments of principal (or thirty equal payments, if the Company so elects).
Final payment percentage of original principal amount	3.15%
Proceeds from term loan		$ 55.4
Legal and consulting fees		0.6
CRG Term Loan
Debt Instrument [Line Items]
Debt extinguishment loss		2.4
Write-offs of unamortized debt discount and debt issuance costs		$ 0.3

Debt - Scheduled Future Payment

Debt - Scheduled Future Payments on Term Loan (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Long-term portion	$ 55,489	$ 55,364
SVB Term Loan
Debt Instrument [Line Items]
The remainder of 2019	0
2020	1,555
2021	18,667
2022	18,667
2023	17,111
Total future principal payments	56,000
Less: unamortized debt discount	(511)
Carrying value of long-term debt	55,489
Less: current portion	0
Long-term portion	$ 55,489

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Millions	Sep. 10, 2019Patent	May 31, 2019ft²	Jun. 30, 2018	Apr. 30, 2018ft²	Jun. 30, 2014ft²	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)ft²	Sep. 30, 2018USD ($)
Operating Leased Assets [Line Items]
Weighted-average remaining lease term							5 years 7 months 6 days
Weighted-average discount rate							7.70%
Rent expense | $						$ 0.5		$ 0.9
Number of patents infringes | Patent	2
Purchase commitments | $							$ 4.9
Lease Agreement | Oakwood Village, Ohio
Operating Leased Assets [Line Items]
Area of land							19,800
Lease agreement, expiration date							Oct. 31, 2021
Lease Agreement | Mountain View, California
Operating Leased Assets [Line Items]
Area of land				24,600	25,500
Lease agreement, expiration date			Jul. 31, 2025	Dec. 31, 2025	Nov. 30, 2019
Option to extend, description operating lease			extend the term of the lease agreement through July 2025
Option to extend, existence operating Lease			true
Lease commencement date				2018-12
Lease Agreement | Mountain View, California | Maximum
Operating Leased Assets [Line Items]
Lease agreement, renewal term				5 years
Sub-Lease Agreement | Denver, Colorado
Operating Leased Assets [Line Items]
Area of land		19,800
Lease agreement, expiration date		May 31, 2021
Lease commencement date		2019-06

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Lease Costs Arising From Lease Transactions (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
Operating lease cost	$ 782	$ 2,085

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Cash Flow Transactions Arising From Lease Transactions (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 1,742
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 1,647	$ 0

Commitments and Contingencies_4

Commitments and Contingencies - Schedule of Future Minimum Payments and Interest Expense for Operating Leases (Detail) $ in Thousands	Sep. 30, 2019USD ($)
Operating Lease Liabilities Payments Due [Abstract]
The remainder of 2019	$ 710
2020	3,148
2021	2,831
2022	2,496
2023	2,571
2024	2,604
Thereafter	1,924
Total undiscounted cash flows	16,284
Less: imputed interest	(3,078)
Present value of lease liabilities	$ 13,206

Commitments and Contingencies_5

Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Detail) $ in Thousands	Dec. 31, 2018USD ($)
Operating Leases Future Minimum Payments Due [Abstract]
2019	$ 2,070
2020	2,353
2021	2,424
2022	2,496
2023	2,571
Thereafter	4,532
Total future minimum payments	$ 16,446

Revenue - Summary of Revenue Di

Revenue - Summary of Revenue Disaggregated by Types and Geography (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation Of Revenue [Line Items]
Product, service and distribution rights revenue	$ 20,862	$ 17,666	$ 71,313	$ 60,299
Product
Disaggregation Of Revenue [Line Items]
Product, service and distribution rights revenue	18,696	16,492	65,475	57,237
Service
Disaggregation Of Revenue [Line Items]
Product, service and distribution rights revenue	2,048	1,056	5,482	2,706
Distribution Rights
Disaggregation Of Revenue [Line Items]
Product, service and distribution rights revenue	118	118	356	356
U.S.
Disaggregation Of Revenue [Line Items]
Product, service and distribution rights revenue	7,247	6,753	31,488	27,239
U.S. | Product
Disaggregation Of Revenue [Line Items]
Product, service and distribution rights revenue	6,107	6,187	28,394	25,775
U.S. | Service
Disaggregation Of Revenue [Line Items]
Product, service and distribution rights revenue	1,140	566	3,094	1,464
Outside of U.S. ("OUS")
Disaggregation Of Revenue [Line Items]
Product, service and distribution rights revenue	13,615	10,913	39,825	33,060
Outside of U.S. ("OUS") | Product
Disaggregation Of Revenue [Line Items]
Product, service and distribution rights revenue	12,589	10,305	37,081	31,462
Outside of U.S. ("OUS") | Service
Disaggregation Of Revenue [Line Items]
Product, service and distribution rights revenue	908	490	2,388	1,242
Outside of U.S. ("OUS") | Distribution Rights
Disaggregation Of Revenue [Line Items]
Product, service and distribution rights revenue	$ 118	$ 118	$ 356	$ 356

Revenue - Additional Informatio

Revenue - Additional Information (Detail)	Aug. 31, 2016	Dec. 31, 2014USD ($)Installment	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)
Revenues [Line Items]
Distribution fees			$ 20,862,000	$ 17,666,000	$ 71,313,000	$ 60,299,000
Long-term trade receivables			200,000		$ 200,000		$ 400,000
Long-term trade credit maintenance services term					1 year
Allowances for doubtful accounts			0		$ 0		$ 0
Deferred revenue, recognized			2,400,000	12,200,000	11,900,000	18,300,000
Company recognized revenue from performance obligations satisfied in a prior period			0		$ 900,000
Minimum
Revenues [Line Items]
Expected long-term trade receivables collection period					3 years
Maximum
Revenues [Line Items]
Expected long-term trade receivables collection period					4 years
Itochu Corporation Agreement
Revenues [Line Items]
Number of installments | Installment		3
Remaining term of distribution agreement	8 years 6 months
Itochu Corporation Agreement | Distribution Rights
Revenues [Line Items]
Distribution fees		$ 4,000,000	$ 100,000	$ 100,000	$ 400,000	$ 400,000

Equity Financing - Additional I

Equity Financing - Additional Information (Detail) - USD ($)	Aug. 17, 2018	Aug. 14, 2018	Feb. 28, 2018	Jan. 31, 2017	Sep. 30, 2016	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Jan. 31, 2019	Dec. 31, 2018	Apr. 30, 2017
Subsidiary Sale Of Stock [Line Items]
Common stock sold							$ 984,000			$ 952,000
2017 Placement Warrants
Subsidiary Sale Of Stock [Line Items]
Warrants to purchase common stock, shares				1,720,512
Warrant exercise price				$ 3.17			$ 3.17
Warrant expiration date				Jan. 31, 2024
Warrant exercisable date				Jul. 31, 2017
Warrant expiration period				7 years
2016 Placement Warrants
Subsidiary Sale Of Stock [Line Items]
Warrants to purchase common stock, shares					1,380,745
Warrant exercise price					$ 2.95		$ 2.95
Warrant expiration period					7 years		7 years
Underwriters | Common Stock
Subsidiary Sale Of Stock [Line Items]
Underwriting agreement date		Aug. 14, 2018
Number of shares issued in transaction		16,216,217
Sale of stock, price		$ 9.25
Option to purchase additional shares		30 days
Aggregate proceeds from issuance of common stock	$ 161,900,000
Underwriters | Common Stock | Maximum
Subsidiary Sale Of Stock [Line Items]
Number of additional shares issued in transaction		2,432,432
March 2018 Direct Registered Offering
Subsidiary Sale Of Stock [Line Items]
Proceed from private placement and equity issuances, gross			$ 59,100,000
March 2018 Direct Registered Offering | Common Stock
Subsidiary Sale Of Stock [Line Items]
Stock issued during period			4,090,000
March 2018 Direct Registered Offering | Series A Convertible Preferred Stock
Subsidiary Sale Of Stock [Line Items]
Stock issued during period			3,000,581
March 2018 Direct Registered Offering Warrants
Subsidiary Sale Of Stock [Line Items]
Warrants to purchase common stock, shares			1,418,116
Warrant exercise price			$ 8.31
Warrant expiration date			Mar. 31, 2025
2017 Private Placement | Common Stock
Subsidiary Sale Of Stock [Line Items]
Number of shares issued in transaction				8,602,589
Proceed from private placement and equity issuances, gross				$ 26,100,000
2016 Private Placement | Common Stock
Subsidiary Sale Of Stock [Line Items]
Number of shares issued in transaction					4,602,506
Proceed from private placement and equity issuances, gross					$ 13,800,000
At The Market Offering Program
Subsidiary Sale Of Stock [Line Items]
Aggregate proceeds from issuance of common stock							$ 0	$ 278,000
Common stock sold						$ 300,000	$ 40,400,000	$ 300,000
At The Market Offering Program | Maximum
Subsidiary Sale Of Stock [Line Items]
Maximum aggregate offering price				$ 75,000,000					$ 250,000,000
Maximum common stock saleable shares, value									$ 100,000,000		$ 50,000,000
At The Market Offering Program | Common Stock
Subsidiary Sale Of Stock [Line Items]
Stock issued during period						18,648,649		18,681,746

Warrants - Additional Informati

Warrants - Additional Information (Detail) $ / shares in Units, $ in Thousands	Sep. 29, 2019shares	Aug. 31, 2015$ / sharesshares	Jul. 31, 2015$ / sharesshares	Sep. 30, 2019USD ($)shares	Sep. 30, 2018USD ($)	Mar. 31, 2018USD ($)$ / sharesshares	Sep. 30, 2019USD ($)shares	Sep. 30, 2018USD ($)	Dec. 31, 2013$ / sharesshares
Common Stock Warrants [Line Items]
Placement warrants not excercised and remained outstanding				2,156,153			2,156,153
Gain (loss) related to change in fair value | $							$ 4,674	$ 116
2018 Direct Registered Offering | Common Stock
Common Stock Warrants [Line Items]
Warrants issued						1,418,116
Exercise price | $ / shares						$ 8.31
Common stock warrants, expiration date						Mar. 31, 2025
Proceed from private placement and equity issuances, gross | $						$ 59,100
Fair value of warrants upon issuance | $						$ 7,400
Warrants, fair value measurement inputs						7 years
Allocated portion of proceeds from issuance of stock and warrants | $						$ 6,600
2018 Direct Registered Offering | Common Stock | Expected Volatility
Common Stock Warrants [Line Items]
Warrants, fair value measurement inputs						0.625
2018 Direct Registered Offering | Common Stock | Risk-free Interest Rate
Common Stock Warrants [Line Items]
Warrants, fair value measurement inputs						0.028
2018 Direct Registered Offering | Common Stock | Expected Dividend Yield
Common Stock Warrants [Line Items]
Warrants, fair value measurement inputs						0
Equity Classified Common Stock Warrants
Common Stock Warrants [Line Items]
Warrants issued									128,231
Exercise price | $ / shares									$ 5.84
Number of warrant exercised	128,231
Stock issued during period	36,457
Placement warrants not excercised and remained outstanding				0			0
2015 Placement Equity Classified Common Stock Warrants | Insiders
Common Stock Warrants [Line Items]
Warrants issued		198,760	198,760
Exercise price | $ / shares		$ 5	$ 5
Number of warrant exercised	159,010
Stock issued during period	92,487
Placement warrants not excercised and remained outstanding				39,750			39,750
Warrant expiration period		5 years	5 years
2016 and 2017 Placement Warrants | Common Stock
Common Stock Warrants [Line Items]
Gain (loss) related to change in fair value | $				$ 13,500	$ (6,700)		$ 8,600	$ 400

Warrants - Schedule of Key Term

Warrants - Schedule of Key Terms of Placement Warrants (Detail) - $ / shares	1 Months Ended		9 Months Ended
	Jan. 31, 2017	Sep. 30, 2016	Sep. 30, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants Exercised			683,994
Warrants Outstanding			2,156,153
2017 Placement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Issuance Date			2017-01
Term	7 years
Exercise Price Per Share	$ 3.17		$ 3.17
Warrants Exercised			90,642
Warrants Outstanding			1,618,890
2016 Placement Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Issuance Date			2016-08
Issuance Date			2016-09
Term		7 years	7 years
Exercise Price Per Share		$ 2.95	$ 2.95
Warrants Exercised			593,352
Warrants Outstanding			537,263

Warrants - Summary of Assumptio

Warrants - Summary of Assumptions to Use Option Pricing Model (Detail)	Sep. 30, 2019	Dec. 31, 2018
2017 Placement Warrants | Expected Term
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Expected term (in years)	4 years 3 months 18 days	5 years 1 month 6 days
2017 Placement Warrants | Expected Volatility
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs	0.679	0.608
2017 Placement Warrants | Risk-free Interest Rate
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs	0.016	0.025
2017 Placement Warrants | Expected Dividend Yield
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs	0	0
2016 Placement Warrants | Expected Term
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Expected term (in years)	3 years 10 months 24 days	4 years 8 months 12 days
2016 Placement Warrants | Expected Volatility
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs	0.673	0.609
2016 Placement Warrants | Risk-free Interest Rate
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs	0.016	0.025
2016 Placement Warrants | Expected Dividend Yield
Fair Value Inputs1 Liabilities Quantitative Information [Line Items]
Warrants, fair value measurement inputs	0	0

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Company's Stock Option Activity and Related Information (Detail) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares
Shares Available for Grant
Shares Available for Grant, Beginning balance	1,908,626
Shares Available for Grant, Additional options authorized	3,853,280
Shares Available for Grant, Options granted	(2,624,505)
Shares Available for Grant, Options canceled	553,585
Shares Available fot Grant, Withheld shares to pay for taxes on RSU released shares	253,986
Shares Available for Grant, RSUs granted	(708,144)
Shares Available for Grant, RSUs canceled	70,732
Shares Available for Grant, Ending balance	3,307,560	1,908,626
Number of Stock Options Outstanding
Number of Stock Options Outstanding, Beginning balance	11,603,708
Number of Stock Options Outstanding, Options granted	2,624,505
Number of Stock Options Outstanding, Options exercised	(2,219,251)
Number of Stock Options Outstanding, Options canceled	(553,585)
Number of Stock Options Outstanding, Ending balance	11,455,377	11,603,708
Number of Stock Options Outstanding, Vested and exercisable	4,575,393
Number of Stock Options Outstanding, Vested and expected to vest	10,793,250
Weighted- Average Exercise Price
Weighted- Average Exercise Price, Beginning balance | $ / shares	$ 6.64
Weighted- Average Exercise Price, Options granted | $ / shares	8.19
Weighted- Average Exercise Price, Options exercised | $ / shares	4.34
Weighted- Average Exercise Price, Options canceled | $ / shares	6.73
Weighted- Average Exercise Price, Ending balance | $ / shares	7.58	$ 6.64
Weighted- Average Exercise Price, Vested and exercisable | $ / shares	6.25
Weighted- Average Exercise Price, Vested and expected to vest | $ / shares	$ 7.38
Weighted- Average Remaining Contractual Life (Years)
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	7 years 10 months 24 days	7 years 7 months 6 days
Weighted- Average Remaining Contractual Life (Years), Vested and exercisable	6 years 2 months 12 days
Weighted- Average Remaining Contractual Life (Years), Vested and expected to vest	7 years 8 months 12 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value | $	$ 1,011	$ 10,151
Aggregate Intrinsic Value, Vested and exercisable | $	1,010
Aggregate Intrinsic Value, Vested and expected to vest | $	$ 1,010

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average grant date fair value of options granted, per share				$ 4.71	$ 5.02
Grant date fair values of options vested				$ 11,400,000	$ 4,300,000
Aggregate intrinsic values of options exercised				7,800,000	11,600,000
Unrecognized compensation cost		$ 29,000,000		$ 29,000,000
Weighted average period for recognition of compensation costs				2 years 10 months 24 days
Total payments for employees’ tax obligations				$ 2,410,000	0
RSUs Granted				708,144
Stock based compensation expenses		4,910,000	$ 7,179,000	$ 14,369,000	10,052,000
Stock-based compensation expense capitalized		0	$ 0	$ 0	$ 0
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average period for recognition of compensation costs				1 year 10 months 24 days
Total grant date fair value of RSUs				$ 5,500,000
Total fair value of RSUs vested				$ 5,900,000
Total shares withheld of RSUs				300,000
Total payments for employees’ tax obligations				$ 2,400,000
RSUs Granted					1,800,000
Stock based compensation expenses					$ 1,200,000
Unrecognized stock based compensation cost		$ 12,700,000		$ 12,700,000
Shares expected to vest		1,617,702		1,617,702
Minimum | Employees | Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	2 years
Maximum | Employees | Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	3 years

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used in Black-Scholes Option-Pricing Model to Estimate Fair Value of Employee Stock Options at Grant Date (Detail)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Expected term (in years)	6 years	6 years
Expected volatility%	60.70%	60.40%
Risk-free interest rate%	2.40%	2.80%
Expected dividend yield%	0.00%	0.00%

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of RSU Activity (Detail)	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Unvested at December 31, 2018, Number of Shares	1,736,234
RSUs granted, Number of Shares	708,144
RSUs vested, Number of Shares	(631,252)
Unvested at September 30, 2019, Number of Shares	1,813,126
Vested and unreleased, Number of Shares	104,173
Outstanding at September 30, 2019, Number of Shares	1,917,299
Unvested at December 31, 2018, Weighted Average Grant Date Fair Value | $ / shares	$ 9.65
RSUs granted, Weighted Average Grant Date Fair Value | $ / shares	7.79
RSUs vested, Weighted Average Grant Date Fair Value | $ / shares	9.40
Unvested at September 30, 2019, Weighted Average Grant Date Fair Value | $ / shares	$ 9.13

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 4,910	$ 7,179	$ 14,369	$ 10,052
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	377	511	1,221	1,061
Selling and Marketing
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	368	234	980	555
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 4,165	$ 6,434	$ 12,168	$ 8,436

Income Tax - Additional Informa

Income Tax - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0	$ 0	$ 0
Federal and state effective tax rate before valuation allowance			24.00%
Unrecognized tax benefits	$ 2,100,000		$ 2,100,000		$ 1,600,000
Accrued interest and penalties related to uncertain tax positions			$ 0		$ 0

Net Loss Per Share - Anti-Dilut

Net Loss Per Share - Anti-Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted net loss per share	15,654,522	17,922,161	16,019,965	15,541,124
Series A Convertible Preferred Stock (If Converted)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted net loss per share	0	0	0	494,601
Options To Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted net loss per share	11,350,034	11,769,686	10,613,157	10,028,174
Common Stock Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted net loss per share	3,866,555	4,694,837	4,200,541	4,441,885
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted net loss per share	437,933	1,457,638	1,206,267	576,464

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	1 Months Ended	9 Months Ended
	Dec. 31, 2004	Sep. 30, 2019	Sep. 30, 2018
Related Party Transaction [Line Items]
Percentage of royalty expense based on net sales		1.00%
Cost of Revenue
Related Party Transaction [Line Items]
Royalty Expense		$ 600,000	$ 500,000
University Of Florida Research Foundation | Licensing Agreements
Related Party Transaction [Line Items]
Common Stock granted in exchange for licensing	33,652
Percentage of royalty payment based on sale	1.00%
Royalty payment per quarter	$ 100,000